has been cited by the following article(s):
|
[1]
|
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11
Frontiers in Medicine,
2025
DOI:10.3389/fmed.2025.1604319
|
|
|
|
|
[2]
|
Functional and Genomic Insights into Clostridium butyricum MCC0233: Probiotic Features and Safety Assessment
Probiotics and Antimicrobial Proteins,
2025
DOI:10.1007/s12602-025-10842-6
|
|
|
|
|
[3]
|
Complete Genome Sequence ofBifidobacterium longumW11 (LMG P-21586), Used as a Probiotic Strain
Genome Announcements,
2017
DOI:10.1128/genomeA.01659-16
|
|
|
|
|
[4]
|
Chemical and biological properties of the novel exopolysaccharide produced by a probiotic strain of Bifidobacterium longum
Carbohydrate Polymers,
2017
DOI:10.1016/j.carbpol.2017.07.039
|
|
|
|
|
[5]
|
Bifidobacteria—Insight into clinical outcomes and mechanisms of its probiotic action
Microbiological Research,
2016
DOI:10.1016/j.micres.2016.07.001
|
|
|
|
|
[6]
|
The Possible Innovative Use of Bifidobacterium longum W11 in Association With Rifaximin
Journal of Clinical Gastroenterology,
2016
DOI:10.1097/MCG.0000000000000683
|
|
|
|